Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-01-09 00:00:00 ET · period of report 2024-01-05 · accession 0001714899-24-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-01-09 | 2024-01-05 | DNLI | Watts Ryan J. | Pres, CEO, Dir | S - Sale | $19.43 | -17.5K | 2.28M | -0.8% | -$339.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-05 | S | D | 17,483 | $19.43 | 2,276,181 | I See footnote | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.36 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 51,060 restricted stock units held by the Reporting Person. (F4) The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. |